Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
  • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• This invention relates to 5-alkylpyridopyrimidines as inhibitors of cyclin- dependent kinases, particularly cyclin-dependent kinase 4.
• the compounds of the invention are useful for the treatment of inflammation, cell proliferative diseases such as cancer and restenosis, and neurodegenerative diseases such as Alzheimer's disease.
• Cyclin-dependent kinases and related serine/threonine protein kinases are cellular enzymes that perform essential functions in regulating cell division and proliferation.
• the cyclin-dependent kinase catalytic units of which nine have been identified, are activated by regulatory units known as cy dines.
• the cyclin- dependent kinases include (Cdk) Cdkl, Cdk2, Cdk4, Cdk5, Cdk6, and Wee- 1 kinase. Increased activity or temporally abnormal activation of these kinases results in development of human tumors and other proliferative disorders such as restenosis.
• Compounds that inhibit Cdks either by blocking the interaction between a cyclin and its kinase partner, or by binding to and inactivating the kinase, cause inhibition of cell proliferation and thus are useful for treating tumors and other abnormally proliferating cells.
• flavopiridol is a flavonoid that is a potent inhibitor of Cdk2 and Cdk4, and has been shown to inhibit several types of breast and lung cancer cells (Kaur et al, J Natl. Cancer Inst., 1992;84:1736-1740; Kaur et al., Int. J. Oncol, 1996;9:1143-1168).
• Olomoucine is a flavonoid that is a potent inhibitor of Cdk2 and Cdk4
• [2-(hydroxyethylamine)-6-benzylamine-9-methylpurme] is a potent inhibitor of Cdk2 and Cdk5 (Vesely et al, Eur. J. Biochem., 1994;224:771-786), and has been shown to inhibit proliferation of approximately 60 different human tumor cell lines used by the National Cancer Institute (NCI) to screen for new cancer therapies (Abraham et al., Biol. Cell, 1995;83:105-120).
• Cdk inhibitors have been shown to treat cardiovascular disorders such as restenosis and atherosclerosis.
• Other diseases in which Cdk inhibitors are useful include those caused by a variety of infectious agents, including DNA and RNA viruses, and inflammatory disorders such as rheumatoid arthritis.
• An object of this invention is to provide a group of small molecular weight organic compounds that are potent Cdk inhibitors, and as such are useful for preventing and treating diseases caused by abnormally proliferating cells.
• This invention provides 5 -alkyl pyridopyrimidines that are useful for treating inflammation, cell proliferative diseases such as cancer and restenosis, and neurodegenerative diseases such as Alzheimer's disease.
• the compounds of the invention display unexpected improvements in pharmacokinetic properties over prior art compounds, including unanticipated metabolic stability and low clearance rates.
• the compounds of the invention are unexpectedly selective inhibitors of Cdk4.
• the compounds of the invention are readily synthesized, and can be administered to patients by a variety of methods.
• the compounds of the invention are those having the structure of Formula I:
• R2 is (a) hydrogen; (b) lower alkyl optionally substituted with one, two, or three groups independently selected from halogen, hydroxy, lower alkoxy, amino, mono- or dialkylamino, carboxy, alkoxycarbonyl, thio alkyl, nitrile, aryl, heteroaryl, or a carbocyclic group containing from 3 to 7 members, up to two of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen; or
• R3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR 4 , -CO 2 R 4 , -CONR 4 R 5 ,
• Y is N or CR 7 ;
• R9 is lower alkyl, haloalkyl, or aryl
• X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR 4 R 5 , -N(0)R 4 R 5 ,
• T is O, S, NR 4 , N(0)R 4 NR 4 R 5 W, or CR 4 R 5 ;
• Q is O, S, NR 4 , N(O)R 4 NR 4 R 5 W, C0 2 , or a carbocyclic group containing from
• 3 to 7 members up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono or dialkylamino;
• R6 is lower alkyl, haloalkyl, or aryl
• R 7 is NR 4 R 5 , N(0)R 4 R 5 , NR 4 R 5 R9 ⁇ , OH, OR 4 , SR 4 , halo, COR 4 , (CH 2 ) n R 4 ,
• W is an anion
• R 4 and R 5 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (CH 2 ) n Ar, arylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl, or R 4 and R 5 together with the nitrogen to which they are attached form a carbocyclic ring containing 3 to 8 members, up to four of which members are optionally carbonyl groups or heteroatoms independently selected from oxygen, sulfur, S(O), S(0) 2 , and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, three, or four groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, aminoalkylcarbonyl, trifluoromethyl, trifluoromethylalkyl, trifluoromethyl
• R 4 additionally can be lower alkyl unsubstituted or substituted with one, two, or three groups independently selected from halogen, 5-oxo-4,5-dihydro- lH-l,2,4-triazol-3-yl-sulfanyl, 5-oxo-4,5-dihydro-lH-l,2,4-triazol-3-yl- sulf ⁇ nyl, 5-oxo-4,5-dihydro-lH-l,2,4-triazol-3-yl-sulfony
• R 7 and Z are as defined above, or can be taken together with the carbons to which they are attached to form
• G and J are independently C ⁇ 2 , NH, or O;
• B is NH, S, CH 2 , or O;
• D is C or N, provided that Rl 0 is nothing when D is N; and RlO and Rl 1 are independently hydrogen, halogen, lower alkyl, lower alkoxy, or alkylcarbonyl.
• Preferred compounds have Formula I wherein Y is CR 7 .
• preferred compounds are those wherein R 7 is NR R 5 , and R 4 and R 5 are taken together with the N to which they are attached to form a ring such as piperazine, piperidine, pyrrolidine, morpholine, each of which can be optionally substituted.
• the present invention also provides pharmaceutical compositions that comprise a compound of Formula I together with a pharmaceutically acceptable diluent, carrier, or excipient.
• the present invention also provides methods for inhibiting cyclin-dependent kinase and growth factor-mediated kinase enzymes.
• the present invention also provides a method of treating subjects suffering from diseases caused by cellular proliferation.
• the method entails inhibiting proliferation of tumorigenic cells of epithelial origin and vascular smooth muscle proliferation, and/or cellular migration by administering a therapeutically effective amount of a compound of Formula I to a subject in need of treatment.
• the invention also provides compounds useful in the diagnosis and treatment of cancer, psoriasis, vascular smooth muscle cell proliferation associated with atherosclerosis and postsurgical vascular stenosis and restenosis in mammals.
• the present invention also provides a method of treating subjects suffering from diseases caused by DNA tumor viruses such as herpes viruses.
• novel compounds encompassed by the instant invention are those described by the general Formula I set forth above, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
• X, Y, Z, and R ⁇ are as defined above for Formula I.
• Preferred compounds of Formula II are those in which X and Z are independently hydrogen, Cl, or F; Y is CR 7 ; and R ⁇ is hydrogen, Cl, F, Br, or CN.
• Especially preferred compounds of Formula III are those in which X and Z are independently hydrogen, Cl, or F; Y is CR 7 ; and R ⁇ is hydrogen, Cl, F, Br, or CN.
• Preferred compounds of Formula IV are those in which X and Z are independently hydrogen, Cl, or F; Y is CR 7 ; and R ⁇ is hydrogen, Cl, F, Br, or CN.
• the most preferred invention compounds have the Formula V
• R2 is alkyl or cycloalkyl
• R3 is hydrogen or halo
• R9 is alkyl
• X and Z independently are hydrogen or halo
• R 7 is NR 4 R 5 ;
• R 4 and R 5 are taken together with the nitrogen to which they are attached to form a 5- or 6-membered carbocyclic ring, optionally containing an oxygen, nitrogen, or sulfur heteroatom, and optionally substituted with alkyl or substituted alkyl groups.
• Especially preferred compounds of Formula V are those wherein R 7 is
• alkyl By “alkyl,” “lower alkyl,” and “ ⁇ -CI Q alkyl” in the present invention is meant a straight or branched hydrocarbon radical having from 1 to 10 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, iso-pentyl, n-hexyl, and the like.
• halogen in the present invention is meant fluorine, bromine, chlorine, and iodine.
• Alkenyl means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one double bond and includes ethenyl, 3-buten-l-yl, 2-ethenylbutyl, 3-hexen-l-yl, and the like.
• Alkynyl means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one triple bond and includes ethynyl, 3-butyn-l-yl, propynyl, 2-butyn-l-yl, 3-pentyn-l-yl, and the like.
• Cycloalkyl means a monocyclic or polycyclic hydrocarbyl group such as cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, norpinanyl, decalinyl, norbornyl, cyclohexyl, and cyclopentyl.
• groups can be substituted with groups such as hydroxy, keto, amino, alkyl, and dialkylamino, and the like. Also included are rings in which 1 to 3 heteroatoms replace carbons.
• heterocyclyl means a cycloalkyl group also bearing at least one heteroatom selected from O, S, or N, examples being oxiranyl, pyrrolidinyl, piperidyl, tetrahydropyran, and morpholine.
• alkoxy straight or branched chain alkoxy groups having 1-10 carbon atoms, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and
• alkoxy refers to polyethers such as -0-(CH ) 2 -0- CH3, and the like.
• Alkanoyl groups are alkyl groups linked through a carbonyl, i.e., C1 -C5-C(0)-. Such groups include formyl, acetyl, propionyl, butyryl, and isobutyryl.
• acyl means an alkyl or aryl (Ar) group bonded through a carbonyl group, i.e., R-C(O)-.
• acyl includes a C1 -C alkanoyl, including substituted alkanoyl, wherein the alkyl portion can be substituted by NR 4 R 5 or a carboxylic or heterocyclic group.
• Typical acyl groups include acetyl, benzoyl, and the like.
• Amide is an amino carbonyl group such as -CONR 4 R 5 .
• the alkyl, alkenyl, alkoxy, and alkynyl groups described above are optionally substituted, preferably by 1 to 3 groups selected from NR 4 R 5 , phenyl, substituted phenyl, thio Cj-Cg alkyl, C ⁇ -C ⁇ alkoxy, hydroxy, carboxy,
• Substituted nitrogen means nitrogen bearing C ⁇ -Cg alkyl or (CH ) n Ph where n is 1, 2, or 3. Perhalo and polyhalo substitution is also included.
• substituted alkyl groups include 2-aminoethyl, 2-hydroxyethyl, pentachloroethyl, trifluoromethyl, 2-diethylaminoethyl,
• 2-ethylsulfanylefhynyl 4-( 1 -piperazinyl)-3 -(butynyl), 3 -phenyl-5-hexynyl, 3-diethylamino-3-butynyl, 4-chloro-3 -butynyl, 4-cyclobutyl-4-hexenyl, and the like.
• Typical substituted alkoxy groups include aminomethoxy, trifluoromethoxy, 2-diethylaminoethoxy, 2-ethoxycarbonylethoxy,
• substituted alkyl, alkenyl, and alkynyl groups include dimethylaminomethyl, carboxymethyl, 4-dimethylamino-3-buten-l-yl, 5-ethylmethylamino-3-pentyn-l-yl, 4-morpholinobutyl, 4-tetrahydropyrinidylbutyl, 3-imidazolidin-l-ylpropyl, 4-tetrahydrothiazol-3-yl- butyl, phenylmethyl, 3-chlorophenylmethyl, and the like.
• anion means a negatively charged counterion such as chloride, bromide, trifluoroacetate, and triethylammonium.
• heteroaryl is meant one or more aromatic ring systems of 5-, 6-, or 7-membered rings containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur.
• heteroaryl groups include, for example, thienyl, furanyl, thiazolyl, triazolyl, imidazolyl, (is)oxazolyl, oxadiazolyl, tetrazolyl, pyridyl, thiadiazolyl, oxadiazolyl, oxathiadiazolyl, thiatriazolyl, pyrimidinyl, (iso)quinolinyl, napthyridinyl, phthalimidyl, benzimidazolyl, and benzoxazolyl.
• a preferred heteroaryl is pyridine.
• aryl is meant an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl), which can be mono-, di-, or trisubstituted with, e.g., halogen, lower alkyl, lower alkoxy, lower alkylthio, trifluoromethyl, lower acyloxy, aryl, heteroaryl, and hydroxy.
• a preferred aryl is phenyl.
• cancer includes, but is not limited to, the following cancers: breast, ovary, cervix, prostate, testis, esophagus, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, adenocarcinoma, bone, colon, adenocarcinoma, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, and leukemia.
• salts refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
• salts refers to the relatively nontoxic, inorganic and organic acid addition salts of compounds of the present invention.
• salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
• Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate and laurylsulphonate salts, and the like.
• alkali and alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium and the like
• non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
• esters of the compounds of this invention include C ⁇ -Cg alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C5-C7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C1 -C4 alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.
• Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary C ⁇ -C5 alkyl amines and secondary C ⁇ -Cg dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C1 -C3 alkyl primary amines and
• Ci-C 2 dialkyl secondary amines are preferred.
• Amides of the compounds of the invention may be prepared according to conventional methods.
• prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood.
• a thorough discussion is provided in T. Higuclii and V. Stella, "Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference.
• the compounds of the present invention are useful for treating cancer (for example, leukemia and cancer of the lung, breast, prostate, and skin such as melanoma) and other proliferative diseases including but not limited to psoriasis,
• a further embodiment of this invention is a method of treating subjects suffering from diseases caused by vascular smooth muscle cell proliferation.
• Compounds within the scope of the present invention effectively inhibit vascular smooth muscle cell proliferation and migration. The method entails inhibiting vascular smooth muscle proliferation, and/or migration by administering an effective amount of a compound of Formula I to a subj ect in need of treatment. .
• the compounds of the present invention can be formulated and administered in a wide variety of oral and parenteral dosage forms, including transdermal and rectal administration. It will be recognized to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt, ester, amide, prodrug, or solvate of a compound of Formula I.
• a further embodiment of this invention is a pharmaceutical composition
• a pharmaceutically acceptable carrier can be either a solid or liquid.
• Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispensable granules.
• a solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
• the carrier is a finely divided solid such as talc or starch which is in a mixture with the finely divided active component.
• the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
• compositions of this invention preferably contain from about 5% to about 70% or more of the active compound.
• Suitable carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
• a preferred form for oral use are capsules, which include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
• cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
• a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
• the active component is dispersed homogeneously therein, as by stirring.
• the molten homogenous mixture is then poured into convenient size molds, allowed to cool, and thereby to solidify.
• Liquid form preparations include solutions, suspensions, and emulsions such as water or water/propylene glycol solutions.
• liquid preparations can be formulated in solution in aqueous polyethylene glycol solution, isotonic saline, 5% aqueous glucose, and the like.
• Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
• Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water and mixing with a viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
• solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration.
• liquid forms include solutions, suspensions, and emulsions.
• These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
• Waxes, polymers, microparticles, and the like can be utilized to prepare sustained-release dosage forms.
• osmotic pumps can be employed to deliver the active compound uniformly over a prolonged period.
• the pharmaceutical preparations of the invention are preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component.
• the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
• the therapeutically effective dose of a compound of Formula I will generally be from about 1 mg/kg to about 100 mg/kg of body weight per day. Typical adult doses will be about 50 mg to about 800 mg per day.
• the quantity of active component in a unit dose preparation may be varied or adjusted from about
• composition can, if desired, also contain other compatible therapeutic agents.
• a subject in need of treatment with a compound of Formula I is administered a dosage of about 1 mg to about 500 mg per day, either singly or in multiple doses over a 24-hour period.
• the compounds of the present invention are capable of binding to and inhibiting the activity of proteins having the ability to phosphorylate other proteins, such as cdks, PDGFr, FGFr, c-Src, and EGFr-FL.
• Cdks form complexes with cyclins, and these complexes phosphorylate key proteins allowing cells to proceed through the cell cycle (Meijer L., Progress in Cell Cycle Research, 1995;1:351-363).
• the compounds of this invention inhibit this phosphorylation and therefore can be used as anti-proliferative agents for the treatment of cancer and/or restenosis and other proliferative diseases.
• the compounds of the present invention are also useful research tools for studying the mechanism of action of those kinases, both in vitro and in vivo.
• a 4-substituted amino-2-methansulfanyl- pyrimidine-5-carboxaldehyde is reacted with an organometallic compound, such as, for example, a Grignard reagent, to afford the corresponding secondary alcohol.
• an organometallic compound such as, for example, a Grignard reagent
• the alcohol is subsequently oxidized to the ketone.
• the ketone is then reacted with a trialkyl phosphonoacetate in the presence of base to produce the corresponding 8-substituted-5 -alkyl-2-methylsulfanyl-8H-pyrido [2,3 -d]pyrimidin- 7-one.
• the pyrido-pyrimidine then can be halogenated at the 6-position with a common halogenating agent, such as, for example, N-bromosucccinimide (NBS).
• N-bromosucccinimide N-bromosucccinimide
• the 2-methylsulfanyl derivative is oxidized to the corresponding methylsulfoxide, which is subsequently treated with a desired aniline to afford the 2-phenylamino invention compound.
• a common halogenating agent such as, for example, N-bromosucccinimide (NBS).
• N-bromosucccinimide (NBS) N-bromosucccinimide
• the 2-methylsulfanyl derivative is oxidized to the corresponding methylsulfoxide, which is subsequently treated with a desired aniline to afford the 2-phenylamino invention compound.
• reactive groups such as amines, alcohols, and acids
• protecting groups simply avoid unwanted side reactions.
• Use of protecting groups is common in the art of organic
• Typical hydroxy protecting groups include either forming groups such as benzyl, and acyl groups such as tert-butoxycarbonyl(Boc), formyl, and acetyl.
• Amino protecting groups include benzyl, acyl such as acetyl, and trialkylsilyl groups.
• Carboxylic acid groups typically are protected by conversion to an ester that can be easily hydrolyzed, for example, trichloroethyl, tert-butyl, benzyl, and the like.
• Some of the invention compounds have one or more chiral centers, and thus can exist as individual optical isomers and mixtures thereof.
• Compound 246 (Table 1), for example, can exist as an RS racemate, or as the individual R or S isomer. All individual isomers and mixtures thereof are included in this invention. Individual isomers are readily prepared by a chiral synthesis, or by conventional resolution techniques well-known to those skilled in the art. The invention is illustrated further by the following detailed examples which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in them. The starting materials and various intermediates utilized in the synthesis of invention compounds may be obtained from commercial sources, prepared from commercially available organic compounds, or prepared using well-known synthetic methods. The disclosures in this application of all articles and references, including patents, are incorporated herein by reference.
• the crude product is purified by silica gel chromatography (eluting with 80%-100% ethyl acetate in hexanes) to provide the sulfoxide product as a white solid (0.55 g, 86%).
• 6-Bromo-8-cyclopentyl-5-methyl-2-methylsulfanyl-8H- pyrido[2,3-d]pyrimidin-7-one is oxidized as described in Example 2.
• the sulfoxide is reacted with 4-(N-Boc-piperazin-l-yl)aniline as described in Example 3.
• N-Boc protecting group is removed by hydrolysis as described above for 8-cyclopentyl-6-fluoro-5-methyl-2-methylsulfanyl-8H- pyrido[2,3-d]pyrimidin-7-one to provide 6-Bromo-8-cyclopentyl-5-methyl- 2-(4-piperazin-l-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (compound 35).
• Mp >200°C (dec).
• N-methyl morpholine oxide (1.07 g, 8.6 g), and tetrapropylammonium perruthenate (0.227 g, 0.645 mmol).
• the reaction mixture is stirred at 24°C for 2 hours, and small amounts of additional catalyst are periodically added.
• the reaction mixture is then run through a silica column (1:1, ethyl acetate :hexanes) to yield the titled compound as a light yellow solid (0.74 g, 70%).
• reaction mixture was cooled to room temperature and partitioned between water and EtOAc. The organic layer was washed with brine then dried over MgS ⁇ 4. After filtration and concentrate in vacuo, orange solid was obtained which was purified by column chromatography to yield the product as a yellow solid (0.160 g, 47%).
• EXAMPLE 18 The following compounds are prepared essentially according to the procedures described in Examples 1 to 17 and as illusfrated in Schemes 1 and 2: (a) 8-Cyclopentyl-5-methyl-2-(4-piperazin-l -yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one trifluoroacetic acid salt (Compound 1), mp >215°C (dec);
• the reaction is terminated by addition of 0.1 mL 20% TCA.
• the plate is kept at 4°C for at least 1 hour to allow the substrate to precipitate.
• the wells are then washed five times with 0.2 mL 10% TCA, and 32p incorporation is determined with a beta plate counter (Wallac Inc., Gaithersburg, MD).
• the Cdk4 enzyme assay for IC50 determination and kinetic evaluation is performed as follows. 96-well filter plates (Millipore MADVN6550) are used. The total volume is 0.1 mL containing a final concentration of 20 mM TRIS (tris[hydroxymethyl]aminomethane) (pH 7.4), 50 mM NaCl, 1 mM dithiothreitol,
• PDGFr PDGF receptor
• FGFr FGF receptor
• the fragment is inserted into a baculoviras vector, cotransfected with AcMNPV DNA, and the recombinant virus is isolated.
• SF9 insect cells are infected with the virus to overexpress the protein, and the cell lysate is used for the assay.
• PDGFr and FGFr enzyme assays are performed in 96-well plates (100 ⁇ L/incubation/well), and conditions are optimized to measure the incorporation of 32p from [ ⁇ 3 2p]ATP into a glutamate-tyrosine co-polymer substrate.
• c-Src protein kinase assay is carried out as follows. c-Src kinase is purified from baculovirus infected insect cell lysates using an antipeptide monoclonal antibody directed against the N-terminal amino acids (amino acids
• the antibody covalently linked to 0.65 ⁇ m latex beads, is added to a suspension of insect cell lysis buffer comprised of 150 mM NaCl, 50 mM Tris (pH 7.5), 1 mM DTT, 1% NP-40, 2 M EGTA, 1 mM sodium vanadate, 1 mM PMSF, 1 ⁇ g/mL each of leupeptin, pepstatin, and aprotinin.
• Insect cell lysate containing c-Src protein is incubated with these beads for 3 to 4 hours at 4°C with rotation.
• the beads are rinsed three times in lysis buffer, resuspended in lysis buffer containing 10% glycerol, and frozen. These latex beads are thawed, rinsed three times in assay buffer (40 mM Tris (pH 7.5), 5 mM ⁇ g CI2) and suspended in the same buffer.
• assay buffer 40 mM Tris (pH 7.5), 5 mM ⁇ g CI2
• assay buffer 40 mM Tris (pH 7.5), 5 mM ⁇ g CI2
• ATP containing 0.2 ⁇ Ci [32p]ATP, 5 ⁇ L DMSO containing inhibitors or as a solvent control, and buffer to make the final volume 125 ⁇ L.
• the reaction is started at room temperature by addition of ATP and quenched 10 minutes later by the addition of 125 ⁇ L 30% TCA, 0.1 M sodium pyrophosphate for 5 minutes on ice.
• the plate is then filtered and the wells washed with two 250-mL aliquots of
• the invention compounds will typically be formulated with common excipients, diluents, and carriers to provide compositions that are well-suited for convenient administration to mammals.
• the following examples illustrate typical compositions that are provided in a further embodiment of this invention.
• Compound 12 is mixed with the lactose and cornstarch (for mix) and blended to uniformity to a powder.
• the cornstarch (for paste) is suspended in 6 mL of water and heated with stirring to form a paste.
• the paste is added to the mixed powder, and the mixture is granulated.
• the wet granules are passed through a No. 8 hard screen and dried at 50°C.
• the mixture is lubricated with 1% magnesium stearate and compressed into a tablet.
• the tablets are administered to a patient at the rate of 1 to 4 each day for prevention and treatment of atherosclerosis.

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=22687699

Family Applications (1)

Country Status (36)

Families Citing this family (83)

Family Cites Families (3)

• 2001
  • 2001-01-29 MX MXPA02008535A patent/MXPA02008535A/es not_active Application Discontinuation
  • 2001-01-29 WO PCT/US2001/002657 patent/WO2001070741A1/en active IP Right Grant
  • 2001-01-29 BR BR0109056-9A patent/BR0109056A/pt not_active IP Right Cessation
  • 2001-01-29 CN CN01807590A patent/CN1422268A/zh active Pending
  • 2001-01-29 IL IL15148001A patent/IL151480A0/xx unknown
  • 2001-01-29 DZ DZ013308A patent/DZ3308A1/fr active
  • 2001-01-29 CA CA002401368A patent/CA2401368A1/en not_active Abandoned
  • 2001-01-29 EP EP01905114A patent/EP1268476A1/en not_active Withdrawn
  • 2001-01-29 AU AU2001233028A patent/AU2001233028A1/en not_active Abandoned
  • 2001-01-29 HU HU0300136A patent/HUP0300136A2/hu unknown
  • 2001-01-29 SK SK1247-2002A patent/SK12472002A3/sk unknown
  • 2001-01-29 CZ CZ20022929A patent/CZ20022929A3/cs unknown
  • 2001-01-29 JP JP2001568942A patent/JP2003528101A/ja not_active Abandoned
  • 2001-01-29 NZ NZ520962A patent/NZ520962A/en unknown
  • 2001-01-29 PL PL01358271A patent/PL358271A1/xx not_active Application Discontinuation
  • 2001-01-29 YU YU66502A patent/YU66502A/sh unknown
  • 2001-01-29 EA EA200200802A patent/EA200200802A1/ru unknown
  • 2001-01-29 KR KR1020027011627A patent/KR20020075805A/ko not_active Application Discontinuation
  • 2001-01-29 EE EEP200200506A patent/EE200200506A/xx unknown
  • 2001-01-29 OA OA1200200281A patent/OA12227A/en unknown
  • 2001-01-29 AP APAP/P/2002/002643A patent/AP2002002643A0/en unknown
  • 2001-03-02 TN TNTNSN01036A patent/TNSN01036A1/en unknown
  • 2001-03-05 AR ARP010101039A patent/AR034119A1/es unknown
  • 2001-03-05 SV SV2001000338A patent/SV2001000338A/es not_active Application Discontinuation
  • 2001-03-05 CO CO01017398A patent/CO5280200A1/es not_active Application Discontinuation
  • 2001-03-05 GT GT200100037A patent/GT200100037A/es unknown
  • 2001-03-05 HN HN2001000040A patent/HN2001000040A/es unknown
  • 2001-03-05 PE PE2001000216A patent/PE20011177A1/es not_active Application Discontinuation
  • 2001-03-05 PA PA20018513201A patent/PA8513201A1/es unknown
• 2002
  • 2002-08-23 IS IS6524A patent/IS6524A/is unknown
  • 2002-08-23 CR CR6736A patent/CR6736A/es not_active Application Discontinuation
  • 2002-09-04 MA MA26801A patent/MA26881A1/fr unknown
  • 2002-09-04 ZA ZA200207110A patent/ZA200207110B/en unknown
  • 2002-09-05 NO NO20024235A patent/NO20024235L/no not_active Application Discontinuation
  • 2002-10-02 BG BG107161A patent/BG107161A/xx unknown
  • 2002-10-04 HR HR20020798A patent/HRP20020798A2/xx not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events